Understanding kidney issues caused by cancer immunotherapy
Official title: Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
Funded at Yale University · NIH-10940754 · Data updated 2026-11-12
This study is looking for a special marker in the blood that can help doctors understand and treat kidney problems caused by cancer medications, so they can better help patients who might not respond to regular treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 10, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $755,970 |
| NIH project number | 1R01DK140717-01 |
| Project ID | NIH-10940754 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients receiving immune checkpoint inhibitor therapy who develop acute kidney injury.
✕Less likely to help
Patients who are not undergoing immune checkpoint inhibitor therapy or who do not develop acute kidney injury may not benefit from this research.
What this research studies
This research focuses on patients who experience acute kidney injury due to immune checkpoint inhibitors used in cancer treatment. It aims to identify a specific biomarker, CXCL9, that can help diagnose this condition and predict how well patients will respond to corticosteroid treatment. By analyzing the biological pathways involved, the study seeks to improve treatment strategies for those who do not respond to standard therapies. The research will involve recruiting 400 participants from multiple healthcare systems who are undergoing treatment with immune checkpoint inhibitors.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnosis and treatment for patients experiencing kidney problems related to cancer immunotherapy.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for immune-related adverse events, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Moledina, Dennis G. — Yale University
- Study coordinator: Moledina, Dennis G.
Related research
Other NIH-funded projects on the same topics.
-
Autoimmune diabetes linked to cancer immunotherapy: discovering causes and biomarkers
This grant explores why some people on cancer immunotherapy develop autoimmune diabetes and aims to find biomarkers to predict and prevent it.
-
ctDNA biomarker to guide safety of cancer immunotherapy in inflammatory arthritis
A patient-facing biomarker study using a blood test to detect tumor DNA in people with cancer who develop inflammatory arthritis from immunotherapy, to help doctors pick safer treatment choices.
-
Cross-species study of immune responses to cancer immunotherapy in dogs and humans with invasive bladder cancer
A study using dogs with naturally occurring invasive bladder cancer to help improve immune checkpoint therapies for people with the same disease.
-
Characterizing the psychological symptoms in melanoma patients on immunotherapy
A long-term study follows adults with advanced skin cancer who are starting immune checkpoint therapy to understand the pattern of emotional and psychological symptoms they experience.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Pathway-guided treatment of colon toxicity from immune checkpoint inhibitors
A patient-focused look at a study that aims to understand and improve how immune checkpoint inhibitor therapy causes colon inflammation and how to treat it more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.